Friday, July 10, 2026

pharma · Anorectal Disorder · Localized Primary Osteoarthritis of Both Hips (Diagnosis)

Chia Tai Tianqing

Chia Tai Tianqing clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Lianyungang, CN HQ
366 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Lianyungang, CN
Employees
366
Programs
11
Drugs
15
Patents
0
Intelligence · Clinical Programs

Chia Tai Tianqing projects

4 ClinicalTrials.gov programs sponsored by Chia Tai Tianqing.

Chia Tai Tianqing has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Gum chewing

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co.,

    Recovery of Bowel Function, Due to Gum Chewing

    phase 3 other active

    1 trial
  2. Lidocaine spray

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co.,

    Uterine Bleeding

    phase 3 small molecule completed

    1 trial
  3. Lidocaine spray

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co.,

    Uterine Cervical Dysplasia

    phase 3 other completed

    1 trial
  4. Mevac-A vaccine

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co.,

    HAV

    phase 3 mab completed

    1 trial

Frequently asked questions

How many clinical projects does Chia Tai Tianqing have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.